| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10908820 | Leukemia Research | 2014 | 25 Pages |
Abstract
Bortezomib-based, case-adjusted regimens are in real-life practice effective in salvage therapy offering reliable survival with acceptable toxicity for relapsed/refractory MM patients.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Adam Walter-Croneck, Norbert Grzasko, Maria Soroka-Wojtaszko, Artur Jurczyszyn, Tigran Torosian, Marcin Rymko, Adam Nowicki, Agnieszka Druzd-Sitek, Ewa Lech-Maranda, Elzbieta Madro, Patrycja Zielinska, Iwona Grygoruk-Wisniowska, Danuta Blonska,